AFA
UTHR icon

Abacus FCF Advisors’s United Therapeutics UTHR Stock Holding History

Abacus FCF Advisors’s Portfolio UTHR Stock Details UTHR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-449
Closed -$64K – 114
2016
Q4 		$64K Buy
449
+253
+129% +$32.3K 1.07% 26
2016
Q3 		$23K Sell
196
-12,180
-98% -$1.46M 0.92% 100
2016
Q2 		$1.31M Buy
12,376
+1,616
+15% +$180K 0.85% 90
2016
Q1 		$1.2M Sell
10,760
-3,096
-22% -$392K 0.69% 98
2015
Q4 		$2.17M Buy
13,856
+258
+2% +$37.6K 0.99% 52
2015
Q3 		$1.78M Buy
+13,598
New +$2.18M 0.92% 91

Other funds holding UTHR

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SCM
Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
AL
AJO LP Philadelphia, Pennsylvania $199M AUM 109.68% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Abacus FCF Advisors's UTHR Position: Q1 2017 in Review

Abacus FCF Advisors sold out of United Therapeutics (UTHR) in Q1 2017, closing a stake of 449 shares — an estimated $64K sold.

Abacus FCF Advisors first reported a position in UTHR in Q3 2015 and held it in 6 quarters. The position peaked at $2.17M in Q4 2015. 411 funds tracked by Wall St. Rank hold UTHR as of Q1 2017.

  • Abacus FCF Advisors reported no remaining United Therapeutics position as of Q1 2017 after selling out during the quarter.
  • Abacus FCF Advisors sold 449 United Therapeutics shares in Q1 2017, an estimated $64K.
  • Abacus FCF Advisors first reported a position in United Therapeutics in Q3 2015 and held it in 6 quarters.
  • Abacus FCF Advisors's United Therapeutics position peaked at $2.17M in Q4 2015.
  • 411 funds tracked by Wall St. Rank held United Therapeutics as of Q1 2017.

Based on Abacus FCF Advisors's 13F filing for Q1 2017, filed 8 May 2017.